Quoin Pharmaceuticals, Ltd. (QNRX)Healthcare | Biotechnology | Ashburn, United States | NasdaqCM
4.20 USD
-0.50
(-10.638%) ⇩
(June 12, 2026, 4 p.m.
EDT)
After hours: 4.20 |
Hot Take ↕ | June 7, 2026, 5:39 a.m. EDT
The immediate outlook is severely clouded by a relentless multi-year price collapse and a statistically weak short-term forecast. The stock has endured four consecutive years of negative annual returns, culminating in a catastrophic -100% cumulative loss over the eight-year observation window. This structural deterioration suggests the market has permanently reassessed the business quality downward, rendering any technical bounce highly suspect. While recent headlines regarding orphan drug status and clinical targets offer a narrative of potential revival, the price action—trading near its 52-week low with no recovery in the trailing 14 days—indicates that investors remain deeply skeptical of the commercial viability or timeline for these assets. The statistical model reinforces this pessimism, predicting a further 12.5% decline over the next 45 days with low confidence, reflecting the high volatility and lack of clear directional momentum. Without evidence of a fundamental inflection point where revenue growth or margins stabilize, the risk of capital erosion remains extreme. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.105534 |
| AutoARIMA | 0.108078 |
| AutoETS | 0.110068 |
| AutoTheta | 0.203841 |
| MSTL_115 | 0.321315 |
Forecast horizon: 60 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 1.19 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.455 |
| Excess Kurtosis | -0.42 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 24.777 |
| Market Cap | 8,435,355 |
| Forward P/E | -1.44 |
| Website | https://quoinpharma.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.5011877 |
| Address1 | 42,127 Pleasant Forest Court |
| All Time High | 1,417,500.0 |
| All Time Low | 4.1 |
| Ask | 4.82 |
| Ask Size | 2 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 33,380 |
| Average Daily Volume3 Month | 98,657 |
| Average Volume | 98,657 |
| Average Volume10Days | 33,380 |
| Bid | 4.92 |
| Bid Size | 2 |
| Book Value | 8.756 |
| City | Ashburn |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.2 |
| Current Ratio | 2.868 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,780,012,800 |
| Day High | 4.6899 |
| Day Low | 4.1 |
| Debt To Equity | 24.777 |
| Display Name | Quoin Pharmaceuticals |
| Dividend Date | 1,571,788,800 |
| Earnings Call Timestamp End | 1,710,419,400 |
| Earnings Call Timestamp Start | 1,710,419,400 |
| Earnings Timestamp End | 1,754,915,400 |
| Earnings Timestamp Start | 1,754,483,400 |
| Ebitda | -17,364,748 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.247 |
| Enterprise Value | -4,294,334 |
| Eps Current Year | -6.88 |
| Eps Forward | -2.91 |
| Eps Trailing Twelve Months | -10.07 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.6106 |
| Fifty Day Average Change | -1.4106002 |
| Fifty Day Average Change Percent | -0.25141698 |
| Fifty Two Week Change Percent | -50.118767 |
| Fifty Two Week High | 41.8 |
| Fifty Two Week High Change | -37.6 |
| Fifty Two Week High Change Percent | -0.8995215 |
| Fifty Two Week Low | 4.1 |
| Fifty Two Week Low Change | 0.099999905 |
| Fifty Two Week Low Change Percent | 0.02439022 |
| Fifty Two Week Range | 4.1 - 41.8 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,470,058,200,000 |
| Float Shares | 1,441,405 |
| Forward Eps | -2.91 |
| Forward P E | -1.4432988 |
| Free Cashflow | -9,524,974 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 4 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02634 |
| Held Percent Institutions | 0.52568 |
| Implied Shares Outstanding | 2,008,418 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,744,156,800 |
| Last Split Factor | 1:35 |
| Long Business Summary | Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases. It has a research agreement with Queensland University of Technology. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc. |
| Long Name | Quoin Pharmaceuticals, Ltd. |
| Market | us_market |
| Market Cap | 8,435,355 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_593010770 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -16,990,212 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 9,439,562 |
| Number Of Analyst Opinions | 4 |
| Open | 4.5766 |
| Operating Cashflow | -15,815,738 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 703 980 4182 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 4.2 |
| Post Market Time | 1,781,295,005 |
| Previous Close | 4.7 |
| Price Eps Current Year | -0.61046505 |
| Price Hint | 4 |
| Price To Book | 0.4796711 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.627 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.33333 |
| Region | US |
| Regular Market Change | -0.5 |
| Regular Market Change Percent | -10.6383 |
| Regular Market Day High | 4.6899 |
| Regular Market Day Low | 4.1 |
| Regular Market Day Range | 4.1 - 4.6899 |
| Regular Market Open | 4.5766 |
| Regular Market Previous Close | 4.7 |
| Regular Market Price | 4.2 |
| Regular Market Time | 1,781,294,400 |
| Regular Market Volume | 68,662 |
| Return On Assets | -0.76204 |
| Return On Equity | -2.31176 |
| Sand P52 Week Change | 0.23177934 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 2,008,418 |
| Shares Percent Shares Out | 0.024400001 |
| Shares Short | 48,916 |
| Shares Short Previous Month Date | 1,777,507,200 |
| Shares Short Prior Month | 85,556 |
| Short Name | Quoin Pharmaceuticals, Ltd. |
| Short Percent Of Float | 0.024400001 |
| Short Ratio | 1.86 |
| Source Interval | 15 |
| State | VA |
| Symbol | QNRX |
| Target High Price | 40.0 |
| Target Low Price | 14.0 |
| Target Mean Price | 29.75 |
| Target Median Price | 32.5 |
| Total Cash | 14,043,301 |
| Total Cash Per Share | 7.786 |
| Total Debt | 2,173,733 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -10.07 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 9.45574 |
| Two Hundred Day Average Change | -5.25574 |
| Two Hundred Day Average Change Percent | -0.55582535 |
| Type Disp | Equity |
| Volume | 68,662 |
| Website | https://quoinpharma.com |
| Zip | 20,148-7349 |